Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
Genentech exercises second option to initiate an additional program under the 2020 collaboration agreement CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised its … [Read more…]
